Clinical trialNCT00635492CompletedObservational

CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy

SponsorAstraZenecaEnrollment2,515Type 2 Diabetes Mellitus

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Patients initiating injectable therapy for type 2 diabetes (insulin or exenatide) in usual clinical practice will be enrolled and followed up for two years in order to describe actual practice with regards to the time on initial treatment regime, whether treatment regimens are being modified, what treatment modifications are made, and clinical and patient-reported outcomes.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

James Malone, MD
Eli Lilly and Company
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

96 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Denmark

Research Site
Amager, Denmark
Research Site
Rønne, Denmark

France

Research Site
Toul, France

Germany

Research Site
Alsfeld, Germany
Research
Aschaffenburg, Germany
Research Site
Augsburg, Germany
Research Site
Aßlar, Germany
Research Site
Bad Aibling, Germany
Research Site
Bad Homburg, Germany
Research Site
Bad Mergentheim, Germany
Research Site
Bergheim, Germany
Research Site
Berlin, Germany
Research
Birkenfeld, Germany
Research Site
Bosenheim, Germany
Research Site
Bruchsal, Germany
Research Site
Dortmund, Germany
Research Site
Dresden, Germany
Research Site
Duisburg, Germany
Research Site
Eberswalde, Germany
Research Site
Eilenburg, Germany
Research Site
Eisenach, Germany
Research Site
Erfurt, Germany
Research Site
Essen, Germany
Research Site
Frankfurt, Germany
Research Site
Gebhardshain, Germany
Research Site
Gersfeld, Germany
Research Site
Giessen, Germany
Research Site
Gifhorn, Germany
Research Site
Grassau, Germany
Research Site
Groß-Gerau, Germany
Research Site
Hadmersleben, Germany
Research Site
Halle, Germany
Research Site
Hamburg, Germany
Research Site
Hammelburg, Germany
Research Site
Hennigsdorf, Germany
Research Site
Hohenmölsen, Germany
Research Site
Ismaning, Germany
Research Site
Kutenholz, Germany
Research Site
Köthen, Germany
Research Site
Langen, Germany

56 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Any human insulin or analog insulin given in any regimen by subcutaneous injectionExenatide →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jan 2008
Primary completion: 31 Dec 2011
Completion: 31 Dec 2011
Last update posted: 9 Apr 2015
Registered enrollment: 2,515
Registry id: NCT00635492

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.